VVC
VVC Exploration Corp
stock NYSE

Scynexis $SCYX is currently at the inflection point of a turn around plan.
The company has been stuck in limbo since its approved gynecological asset Brexafemme (Ibrexafungerp) for treating VVC was hit with a manufacturing hold. Today the stock rallied on FDA clarification around Brexafemme that implies GSK(the company Scynexis transferred manufacturing and distribution rights to) will begin manufacturing before EOY.
Despite what it says on some websites SCYX recently executed a 1:8 reverse split and is currently valued around $48m USD. Brookline today reiterated that it believes once reapproved Brexafemme will produce $17m in royalties and milestones next year nearly 1/3 of the current market cap.
The company also has a pipeline of next generation fungerps that are being subsidized by the NIH and the company recently acquired a kidney asset with high potential.
Easy long from here

Scynexis $SCYX is currently at the inflection point of a turn around plan.
The company has been stuck in limbo since its approved gynecological asset Brexafemme (Ibrexafungerp) for treating VVC was hit with a manufacturing hold. Today the stock rallied on FDA clarification around Brexafemme that implies GSK(the company Scynexis transferred manufacturing and distribution rights to) will begin manufacturing before EOY.
Despite what it says on some websites SCYX recently executed a 1:8 reverse split and is currently valued around $48m USD. Brookline today reiterated that it believes once reapproved Brexafemme will produce $17m in royalties and milestones next year nearly 1/3 of the current market cap.
The company also has a pipeline of next generation fungerps that are being subsidized by the NIH and the company recently acquired a kidney asset with high potential.
Easy long from here